治愈性治疗联合转移灶立体定向放疗用于骨转移寡转移性乳腺癌的前瞻性研究
前瞻性研究纳入49例仅骨转移的寡转移性乳腺癌患者(共84个转移灶),先对转移灶行SBRT,再行蒽环和紫杉类治愈性化疗及原发灶手术切除。中位随访19.4个月,中位PFS 18.8个月,1年和2年PFS分别为81.63%和71.43%,1年和2年OS分别为89%和74%,未报告3-4级毒性。
要点
- 仅骨寡转移乳腺癌接受SBRT联合治愈性治疗,2年PFS 71.43%、OS 74%。
- 完成新辅助化疗与手术切除原发灶与PFS改善相关(P=.05和P=.02)。
- 96.4%患者镇痛药需求减少,10.7%出现暂时性疼痛加剧,无3-4级毒性。
核心结论
- 在未经系统治疗的仅骨寡转移乳腺癌患者中,SBRT联合治愈性治疗显示良好结局,强调患者选择与分层的重要性。
研究设计与样本
- 前瞻性研究,纳入1-5个仅骨转移灶的乳腺癌患者,转移灶行SBRT后接受蒽环和紫杉类治愈性化疗及原发灶手术切除。
- 椎体转移者SBRT为30 Gy分3次3天,非椎体转移者为24 Gy分2次2天,疗效评估采用PERCIST。
主要发现
- 共49例患者、84个转移灶入组,中位随访19.4个月(范围1.1-44.4个月)。
- 中位PFS 18.8个月(范围1.1-44.4个月;95% CI,26.512-36.349),1年和2年PFS分别为81.63%和71.43%。
- 中位OS 19.4个月(范围1.56-44.4个月),1年和2年OS分别为89%和74%。
- PFS多因素分析:完成新辅助化疗P=.05、原发灶手术切除P=.02与PFS改善显著相关,激素受体阳性接近显著(P=.07)。
- OS多因素分析:完成新辅助化疗P=.01、接受局部区域放疗P=.038、存在椎体转移P=.038与生存改善显著相关。
关键数值与推荐
- 疼痛控制:96.4%患者镇痛药需求减少,中位疼痛缓解时间2.3个月(IQR,1.0-4.7个月)。
- 毒性:随访期间未报告3-4级毒性,最常见不良事件为暂时性疼痛加剧(疼痛 flare),发生率10.7%。
临床怎么用
- 对未经系统治疗、仅骨寡转移的乳腺癌患者,可考虑转移灶SBRT联合治愈性化疗及原发灶手术切除。
- 治疗前需重视患者选择与分层,以争取最佳疗效。
局限性
- 寡转移性乳腺癌患者群体异质性大,本研究结果需在严格选择的人群中解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A combination of metastasis-directed ablative therapy and curative-intent treatment for oligometastatic breast cancer is an active area of research. We designed this prospective study to explore this approach in a homogenous population of patients with oligometastatic breast cancer with bone-only metastases. METHODS AND MATERIALS: Patients with 1-5 bone-only metastases were included and received stereotactic body radiation therapy (SBRT) to the metastatic site, followed by curative-intent anthracycline and taxane-based chemotherapy and surgical excision of the primary tumor. Patients with vertebral metastases received SBRT as 30 Gy in 3 fractions over 3 days, and those with nonvertebral metastases received 24 Gy 2 two fractions over 2 days. Response assessment was done using PERCIST (PET response criteria in solid tumors). The study was designed to evaluate the progression-free survival (PFS), overall survival (OS), local control rate at the mestastatic site of SBRT, and impact of SBRT on pain control. RESULTS: Between June 2021 and April 2024, a total of 49 patients with a total of 84 metastatic sites were enrolled. After a median follow-up of 19.4 months (1.1-44.4 months), median PFS was 18.8 months (1.1-44.4 months; 95% CI, 26.512-36.349), whereas the 1- and 2-year PFS were 81.63% and 71.43%, respectively. Multivariate analysis for PFS revealed that patients who completed neoadjuvant chemotherapy (P = .05) and underwent surgical excision of the primary tumor (P = .02) experienced significantly improved PFS, and hormone receptor positivity approached significance (P = .07). The median OS for the entire cohort was 19.4 months (1.56-44.4 months), whereas the 1- and 2-year OS were 89% and 74%, respectively. Multivariate analysis for OS revealed significantly improved survival for patients completing neoadjuvant chemotherapy (P = .01), receiving locoregional radiation therapy (P = .038), and presence of vertebral metastasis (P = .038). With SBRT, a high proportion of patients (96.4%) experienced a reduction in their analgesic medication requirements. The median time to achieve a pain response was 2.3 months (IQR, 1.0-4.7 months). The treatment was well-tolerated, with no documented grade 3 to 4 toxicities reported throughout the follow-up period. The most frequently observed adverse event was a temporary exacerbation of pain, known as a pain flare, which occurred in 10.7% of the patient cohort. CONCLUSIONS: Oligometastatic breast cancer is a very heterogeneous group of patients. This study demonstrates excellent outcomes in treatment-naïve, bone-only metastatic patients, emphasizing the need for patient selection. This finding underscores the critical importance of careful patient stratification and selection to achieve optimal therapeutic efficacy.
引用
- Dagar A, Ghosh A, Singhal A, et al. A Study of Curative-approach Treatment Along With Metastasis-Directed Stereotactic Body Radiation Therapy in Bone-Only Oligometastatic Breast Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41389946. doi:10.1016/j.ijrobp.2025.11.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。